VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance.
Weiling LiuChuanwang MiaoShaosen ZhangYachen LiuXiangjie NiuYiyi XiWenjia GuoJiahui ChuAi LinHongjin LiuXinyu YangXinjie ChenCe ZhongYuling MaYuqian WangShihao ZhuShuning LiuWen TanDongxin LinChen WuPublished in: Signal transduction and targeted therapy (2021)
Radiotherapy remains the mainstay for treatment of various types of human cancer; however, the clinical efficacy is often limited by radioresistance, in which the underlying mechanism is largely unknown. Here, using esophageal squamous cell carcinoma (ESCC) as a model, we demonstrate that guanine nucleotide exchange factor 2 (VAV2), which is overexpressed in most human cancers, plays an important role in primary and secondary radioresistance. We have discovered for the first time that VAV2 is required for the Ku70/Ku80 complex formation and participates in non-homologous end joining repair of DNA damages caused by ionizing radiation. We show that VAV2 overexpression substantially upregulates signal transducer and activator of transcription 1 (STAT1) and the STAT1 inhibitor Fludarabine can significantly promote the sensitivity of radioresistant patient-derived ESCC xenografts in vivo in mice to radiotherapy. These results shed new light on the mechanism of cancer radioresistance, which may be important for improving clinical radiotherapy.
Keyphrases
- dna repair
- papillary thyroid
- early stage
- dna damage response
- locally advanced
- endothelial cells
- radiation therapy
- squamous cell
- dna damage
- radiation induced
- cell proliferation
- transcription factor
- squamous cell carcinoma
- childhood cancer
- induced pluripotent stem cells
- lymph node metastasis
- type diabetes
- skeletal muscle
- circulating tumor
- combination therapy